TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company’s Position to be a Leader

Group 1 - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the top AI stocks to buy, with TD Cowen reaffirming a Hold rating and an $88 price target [1] - The company reported a revenue of $334.2 million, with adjusted EBITDA improving to $1.5 million, highlighting its competitive advantage in pharmaceutical R&D efficiency [2] - Management is transitioning a significant portion of xT CDx volume to FDA-approved and Advanced Diagnostic Laboratory Test tracks, with plans for additional FDA filings [3] Group 2 - Tempus AI focuses on precision medicine by utilizing artificial intelligence to analyze healthcare data, offering next-gen sequencing diagnostics and various pathology testing services [4]